Yes, malignant hyperthermia is genetic. It follows an autosomal dominant inheritance pattern, meaning you only need one copy of the altered gene from one parent to be susceptible. If a parent carries the trait, each of their children has a 50% chance of inheriting it. The genetic susceptibility may be as common as 1 in 3,000 people, though most carriers never know unless they’re exposed to specific anesthetic drugs during surgery.
The Genes Involved
The primary gene linked to malignant hyperthermia is RYR1, which accounts for 70% to 80% of confirmed cases. This gene provides instructions for building a protein channel in skeletal muscle cells that controls the release of calcium, the mineral signal that tells muscles to contract. A second gene, CACNA1S, is responsible for roughly 1% of cases. It codes for a different calcium channel protein that works alongside the RYR1 channel. A third gene, STAC3, has also been identified. STAC3 was originally discovered in members of the Lumbee Native American tribe in North Carolina and has since been found in other populations worldwide.
Beyond these three confirmed genes, researchers have mapped at least four additional locations in the genome that appear connected to malignant hyperthermia, but the specific genes at those sites haven’t been identified yet. This means that in about 15% to 30% of people who have a confirmed malignant hyperthermia episode, no known mutation can be found through current genetic testing.
What Happens Inside the Muscle
In someone with a susceptibility mutation, the calcium channel in their muscle cells opens too easily and closes too slowly when exposed to certain anesthetic drugs. This floods the muscle cell with calcium, causing it to lock into a sustained contraction. That unrelenting contraction burns through the cell’s energy supply at a dramatic rate, consuming large amounts of oxygen and producing excess carbon dioxide and heat. As energy stores run out, the muscle cell membrane starts to break down, leaking its contents (potassium, muscle enzymes, and a protein called myoglobin) into the bloodstream.
The result is a rapidly escalating crisis: body temperature can spike dangerously high, muscles become rigid, the heart rhythm becomes unstable, and without immediate treatment the condition can be fatal. Importantly, none of this happens unless the person is exposed to a triggering drug. Someone can carry the mutation their entire life and never experience a single symptom if they’re never given those specific anesthetics.
What Triggers a Reaction
Malignant hyperthermia is triggered by volatile anesthetic gases, the inhaled agents used to keep patients unconscious during surgery. These include halothane, isoflurane, and sevoflurane. A muscle-relaxing drug called succinylcholine, sometimes given at the start of anesthesia to relax the jaw and throat for intubation, is the other major trigger. Occasionally, extreme physical stress or heat may provoke a reaction, though this is far less common and less well understood.
The incidence of actual reactions during anesthesia ranges widely, from about 1 in 5,000 to 1 in 100,000 anesthetic procedures. The wide range exists partly because some reactions are mild and go unrecognized, and partly because not every susceptible person reacts every time they’re exposed. Some carriers have undergone multiple surgeries with triggering agents before experiencing their first episode.
How Susceptibility Is Tested
There are two main ways to find out whether you carry the trait. Genetic testing through a blood sample can look for known mutations in the RYR1 and CACNA1S genes. If a specific mutation is found, the diagnosis is definitive. The limitation is that current testing can only identify known mutations, so a negative genetic test doesn’t completely rule out susceptibility, particularly if there’s a strong family history or a prior suspicious event during surgery.
The gold standard diagnostic tool is the caffeine-halothane contracture test. This requires a surgical biopsy of a small piece of thigh muscle, which is then exposed to caffeine and halothane in a lab. If the muscle contracts beyond a specific force threshold in response to either substance, the person is classified as susceptible. This test has 100% sensitivity, meaning it catches virtually every susceptible person, with specificity between 80% and 97%. The downside is that it requires an invasive muscle biopsy, is only available at specialized testing centers, and can’t be done on very young children.
What This Means for Families
Because malignant hyperthermia follows autosomal dominant inheritance, a single confirmed case in a family has implications for every blood relative. Each first-degree relative (parents, siblings, children) has up to a 50% chance of carrying the same mutation. The standard recommendation is that all biological relatives of a confirmed case should be evaluated, starting with genetic testing if the family’s specific mutation is known.
If you’ve been told a family member had a reaction during surgery, or if “malignant hyperthermia” appears anywhere in your family medical history, it’s worth getting tested before you ever need anesthesia. Carriers can still have surgery safely. Anesthesiologists have well-established protocols using alternative anesthetic drugs that don’t trigger the condition, and operating rooms can be prepared in advance. The danger comes from not knowing you carry the trait, because the very first reaction can be life-threatening.
Many families only discover they carry the mutation after someone has a crisis on the operating table. Because carriers are completely healthy and symptom-free outside of anesthetic exposure, there’s no outward sign of the trait. This is why family screening matters so much. Knowing your status turns a potentially fatal surprise into a straightforward precaution.